Application of computational methods for anticancer drug discovery, design, and optimization

Abstract Developing a novel drug is a complex, risky, expensive and time-consuming venture. It is estimated that the conventional drug discovery process ending with a new medicine ready for the market can take up to 15 years and more than a billion USD. Fortunately, this scenario has recently changed with the arrival of new approaches. Many novel technologies and methodologies have been developed to increase the efficiency of the drug discovery process, and computational methodologies have become a crucial component of many drug discovery programs. From hit identification to lead optimization, techniques such as ligand- or structure-based virtual screening are widely used in many discovery efforts. It is the case for designing potential anticancer drugs and drug candidates, where these computational approaches have had a major impact over the years and have provided fruitful insights into the field of cancer. In this paper, we review the concept of rational design presenting some of the most representative examples of molecules identified by means of it. Key principles are illustrated through case studies including specifically successful achievements in the field of anticancer drug design to demonstrate that research advances, with the aid of in silico drug design, have the potential to create novel anticancer drugs.

[1]  J J Baldwin,et al.  Carbonic anhydrase inhibitors for the treatment of glaucoma , 2023, Медицинская этика.

[2]  Xin Li,et al.  Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach , 2012, BMC Systems Biology.

[3]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[5]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[6]  Suwen Zhou,et al.  Pharmacophore-Based 3D-QSAR Modeling, Virtual Screening and Molecular Docking Analysis for the Detection of MERTK Inhibitors with Novel Scaffold. , 2016, Combinatorial chemistry & high throughput screening.

[7]  Joo Chuan Tong,et al.  Recent advances in computer-aided drug design , 2009, Briefings Bioinform..

[8]  L. Bourgon,et al.  Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. , 2005, Antiviral research.

[9]  Catherine Jessica Lai,et al.  Pharmacophore-based screening targeted at upregulated FN1, MMP-9, APP reveals therapeutic compounds for nasopharyngeal carcinoma , 2016, Comput. Biol. Medicine.

[10]  J. Baselga,et al.  ZD1839 (‘Iressa’)1,2 as an Anticancer Agent , 2012, Drugs.

[11]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[12]  Yi-Wei Chang,et al.  Structure–Activity Relationship Studies of 3‐Aroylindoles as Potent Antimitotic Agents , 2006, ChemMedChem.

[13]  Graham J. Durant,et al.  Proceedings: The pharmacology of cimetidine, a new histamine H2-receptor antagonist. , 1975 .

[14]  Sean Ekins,et al.  Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.

[15]  Jian Yu,et al.  BH3 mimetics to improve cancer therapy; mechanisms and examples. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  Norbert Bischofberger,et al.  Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.

[17]  D. M. Ryan,et al.  4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro , 1993, Antimicrobial Agents and Chemotherapy.

[18]  Sanjay Goel,et al.  Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase , 2003, Expert review of anticancer therapy.

[19]  Roberto Todeschini,et al.  Molecular descriptors for chemoinformatics , 2009 .

[20]  Timothy P. Spicer,et al.  In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632 , 2000, Antimicrobial Agents and Chemotherapy.

[21]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[22]  M. Jarman,et al.  The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. , 1998, Journal of medicinal chemistry.

[23]  J W Black,et al.  The pharmacology of cimetidine, a new histamine H2-receptor antagonist. , 1975, British journal of pharmacology.

[24]  D. Ho,et al.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.

[25]  Mohane Selvaraj Coumar,et al.  Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. , 2009, Journal of medicinal chemistry.

[26]  W. Brass,et al.  New Life Tables for Latin American Populations in the Nineteenth and Twentieth Centuries. , 1969 .

[27]  J. Bajorath,et al.  Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.

[28]  C M Cook,et al.  The three-dimensional x-ray crystal structure of HIV-1 protease complexed with a hydroxyethylene inhibitor. , 1991, Advances in experimental medicine and biology.

[29]  B Rubin,et al.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. , 1977, Science.

[30]  D W Cushman,et al.  Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. , 1977, Biochemistry.

[31]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[32]  Vinita Mishra,et al.  Ligand based virtual screening to find novel inhibitors against plant toxin Ricin by using the ZINC database , 2011, Bioinformation.

[33]  Ming-Sound Tsao,et al.  Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.

[34]  B. Bonavida,et al.  Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies. , 2011, Critical reviews in oncogenesis.

[35]  Brian K Shoichet,et al.  Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.

[36]  A. Zarghi,et al.  Design, Synthesis, and Biological Evaluation of New 2-Phenyl-4H-chromen-4-one Derivatives as Selective Cyclooxygenase-2 Inhibitors , 2014, Scientia pharmaceutica.

[37]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[38]  W. Prince,et al.  Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers , 2002, Journal of clinical pharmacology.

[39]  S. Noha,et al.  Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques , 2011, Bioorganic & medicinal chemistry letters.

[40]  Irene T Weber,et al.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.

[41]  A. Odermatt,et al.  Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases , 2015, Molecules.

[42]  C. Laggner,et al.  Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  Massoud Amanlou,et al.  Potent Human Telomerase Inhibitors: Molecular Dynamic Simulations, Multiple Pharmacophore-Based Virtual Screening, and Biochemical Assays , 2015, J. Chem. Inf. Model..

[44]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[45]  W. L. Jorgensen The Many Roles of Computation in Drug Discovery , 2004, Science.

[46]  F A Quiocho,et al.  The structure of carboxypepidase A. V. Studies of enzyme-substrate and enzyme-inhibitor complexes at 6 A resolution. , 1967, The Journal of biological chemistry.

[47]  Devadasan Velmurugan,et al.  Identification of novel natural inhibitor for NorM – a multidrug and toxic compound extrusion transporter – an insilico molecular modeling and simulation studies , 2017, Journal of biomolecular structure & dynamics.

[48]  Peter J Piliero,et al.  Atazanavir: a novel HIV-1 protease inhibitor , 2002, Expert opinion on investigational drugs.

[49]  M. Ondetti,et al.  Design of angiotensin converting enzyme inhibitors , 1999, Nature Medicine.

[50]  N. Spector,et al.  Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 , 2004, Oncogene.

[51]  Ivet Bahar,et al.  Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. , 2011, Current topics in medicinal chemistry.

[52]  Paul Workman,et al.  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[53]  Sherburne F. Cook,et al.  New Life Tables for Latin American Populations in the Nineteenth and Twentieth Centuries , 1969 .

[54]  L. Kuo,et al.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.

[55]  J F Davies,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[56]  Ping-Chiang Lyu,et al.  Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.

[57]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..

[58]  Maurizio Recanatini,et al.  Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. , 2008, Bioorganic & medicinal chemistry.

[59]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[60]  Honglin Li,et al.  Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. , 2011, Journal of medicinal chemistry.

[61]  Li‐Ping Sun,et al.  Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. , 2016, European journal of medicinal chemistry.

[62]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[63]  O. Rosenheim,et al.  The Ring-system of sterols and bile acids. Part II , 1932 .

[64]  Christian Drosten,et al.  Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro , 2005, Journal of Virology.

[65]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[66]  Vannajan Sanghiran Lee,et al.  Estimation of Inhibitory Effect against Tyrosinase Activity through Homology Modeling and Molecular Docking , 2015, Enzyme research.

[67]  M. Youle,et al.  Clinical potential of a new HIV protease inhibitor. , 1995, Journal of the International Association of Physicians in AIDS Care.

[68]  S Seeber,et al.  Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. , 2003, International journal of clinical pharmacology and therapeutics.

[69]  J. Baselga,et al.  ZD1839 ('Iressa') as an anticancer agent. , 2000, Drugs.

[70]  Irene T. Weber,et al.  Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.

[71]  O. ROSENHEIM,et al.  The Ring System of Sterols and Bile Acids , 1932, Nature.

[72]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[73]  Scott Myers,et al.  Drug discovery—an operating model for a new era , 2001, Nature Biotechnology.

[74]  Tim Eisen,et al.  Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[75]  Dinesh Kumar,et al.  Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database , 2010, Bioinformation.

[76]  M Elliott,et al.  Zanamivir: from drug design to the clinic. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[77]  G. Klebe,et al.  Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. , 2002, Angewandte Chemie.

[78]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  Xiaowu Chen,et al.  Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. , 2000, Current medicinal chemistry.

[80]  J. Irwin,et al.  Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.

[81]  R. Sturdevant,et al.  Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer. , 1975, The New England journal of medicine.

[82]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[83]  David A. Stock,et al.  BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents , 2000, Antimicrobial Agents and Chemotherapy.

[84]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[85]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[86]  Wim G. J. Hol,et al.  PROTEIN CRYSTALLOGRAPHY AND COMPUTER-GRAPHICS TOWARD RATIONAL DRUG DESIGN , 1986 .

[87]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[88]  J. McCauley,et al.  Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. , 1994, Antiviral research.

[89]  Ming-Sound Tsao,et al.  Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.

[90]  Jean-Louis Reymond,et al.  Exploring the chemical space of known and unknown organic small molecules at www.gdb.unibe.ch. , 2011, Chimia.

[91]  Dale J. Kempf,et al.  ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.

[92]  I Judson,et al.  Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.

[93]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[94]  L. Pustilnik,et al.  Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[95]  Faizan Ahmad,et al.  Design and synthesis of a novel class of carbonic anhydrase-IX inhibitor 1-(3-(phenyl/4-fluorophenyl)-7-imino-3H-[1,2,3]triazolo[4,5d]pyrimidin 6(7H)yl)urea. , 2016, Journal of molecular graphics & modelling.

[96]  Andrew P Combs Structure-based drug design of new leads for phosphatase research. , 2007, IDrugs : the investigational drugs journal.

[97]  Alexander Wlodawer,et al.  Rational approach to AIDS drug design through structural biology. , 2002, Annual review of medicine.

[98]  Lester A. Mitscher,et al.  Chapter 36 – Glossary of Terms Used in Medicinal Chemistry (IUPAC Recommendations 1997) , 1998 .

[99]  Corwin Hansch,et al.  Comprehensive medicinal chemistry : the rational design, mechanistic study & therapeutic application of chemical compounds , 1990 .

[100]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[101]  Cheng Luo,et al.  Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. , 2010, Journal of Medicinal Chemistry.

[102]  Irene T. Weber,et al.  Amprenavir complexes with HIV‐1 protease and its drug‐resistant mutants altering hydrophobic clusters , 2010, The FEBS journal.

[103]  Peter W Swaan,et al.  Computational approaches to modeling drug transporters. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[104]  G. Shapiro,et al.  Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. , 2010, Current opinion in investigational drugs.

[105]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[106]  Eduardo E. Arriaga,et al.  New Life Tables for Latin American Populations in the Nineteenth and Twentieth Centuries , 1969 .